This is an evaluation-first program: the physician team reads every case before you fly, before you pay, and before hope gets ahead of evidence. Celva considers neurologic, cardiovascular, and autoimmune cases, in the groups set out below, and takes one on only where the physician team finds a documented rationale and a realistic goal.
Book a callThe families most likely to reach us have already heard every version of hope and every version of no.
Our job isn't to add another "maybe." It's to read the case honestly and say yes, no, or not yet, with reasons.
We only move forward when a case appears clinically appropriate and expectations are realistic. If your case has a plausible indication and reasonable imaging, we'll evaluate carefully. If it doesn't, we'll tell you why not, and where to look next.
In each one the physician team looks for the same things: an indication with biologic plausibility, imaging that matches, and realistic expectations.
Early-to-mid Parkinson's as an adjunct, chronic post-stroke deficit, and peripheral neuropathy where there is still nerve structure to support and inflammation to influence.
Reduced ejection fraction, stable on guideline-directed therapy, still followed by your cardiologist. The evidence is early; we treat it as an adjunct, never a replacement for your cardiac care.
Select MS, dysautonomia, and post-viral conditions with a demonstrated inflammatory component, where systemic immune modulation has a rationale.
Accepted for quality-of-life support only. We are explicit up front: this is palliative, not disease-modifying. Cell therapy does not cure ALS.
Complex disease varies enormously in mechanism, time course, and how reachable it is with cell signaling. MSC therapy has stronger rationale in some indications than others. The whole point of the evaluation is to tell those apart, for your case specifically.
The cell type is matched to the target, not used off the shelf. Across these conditions we build on allogeneic umbilical-cord (Wharton's jelly) MSCs, which secrete higher levels of neurotrophic, immune-modulating, and pro-repair signaling factors than marrow-derived cells, often blended with bone-marrow MSCs depending on the target. That signaling environment, supporting your body's own repair rather than replacing tissue, is the mechanism we rely on, which is also why it has limits.
We don't run blanket "stem cells for Alzheimer's" or "stem cells for autism" marketing, and we never promise a result.
We look at each case on its own: where there is a documented rationale and a realistic goal, the physician team may take it on; where there isn't, we say so plainly. We don't enroll families in expensive therapy when the biologic case isn't there.
What response looks like, and how we read itA call with a patient coordinator comes first. Then your records: diagnosis, imaging, medication history, prior therapy trials, goals.
The physician team reviews your records and imaging against the evidence for your condition. The decision may land here.
When the case merits it, an extended call with the physician team follows. Questions go both ways.
A written answer. Accept with a written plan. Decline with reasons and referrals where appropriate. Defer pending additional imaging or trials.
Often your specialist is right. If you want an honest second read, we'll give one. Many of our answers confirm what your specialist already said, and families still leave with a clearer picture.
Because the biologic case isn't there. A yes from another clinic doesn't make the biology work. We're structured to say what's true, not what's marketable.
For some conditions, active clinical trials are enrolling. We can sometimes point you to those. For others, the honest answer is not yet. Either is more useful than a yes we can't defend.
The first step is a call with a patient coordinator. It's there to decide well, not to fill a schedule.
Book a callNot medical advice. Every candidacy is screened carefully, and an honest no always comes with reasons.